Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.
about
Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatmentAmyloid diseases of the heart: current and future therapiesAmyloidosis and POEMS syndrome.Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Amyloidosis: pathogenesis and new therapeutic options.A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.Light chain amyloidosis 2012: a new era.Future directions in the clinical management of amyloid light-chain amyloidosis.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.Cardioverter-defibrillator implantation in myeloma-associated cardiac amyloidosis.Current treatment of AL amyloidosis.Light chain amyloidosis: the heart of the problem.How to manage primary amyloidosis.Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: results of multicenter analysis.Primary Systemic Amyloidosis (AL)Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
P2860
Q26827340-5D765E7B-A0E1-4C35-A3A4-F3B1F827BDEEQ27023836-6F182445-D5C0-496E-8284-F01D99CB5456Q33867198-2427E558-E890-489F-B414-AA663BDC9574Q34448455-A3B6CFF8-7470-484C-9B7D-809559DF706CQ35111771-E636BA25-0869-4BEC-A9C7-4A69AFFA09F6Q36862339-77E138E4-2950-4E39-B5C9-8F16D7C7E2D6Q37212712-2C71E3F7-880B-4793-98FA-A0B556B6FF74Q37832199-E133A992-C0E6-415F-8D7D-8A090E92BA05Q38072108-F45906EE-2262-4C75-8B75-C2F4BDB39103Q38172998-254565CC-38B7-4540-B204-2AC3252EF1C1Q38928383-B18DF9AE-A0EE-4D1D-9EE4-851ADBFC8443Q39024208-A79FC596-9750-42CA-B654-2B636B423A02Q41593651-AF7CBB9C-A387-4801-BF14-470F069C5918Q42177959-9B9473DB-7F29-4387-9472-FB96FD18113DQ42662215-D41D9460-24D8-4160-8043-E048147E2310Q42958777-E79595F2-9885-499D-8968-6E0BD890F690Q46400142-6D858B5D-1659-4F8A-AA25-D87C9B971962Q46695052-54BB3E13-A446-4894-8E57-6B87ECFE3212Q57904586-8CA7A4F1-E247-45F2-83CB-5935045EE4ABQ58030146-F1F87492-A180-4CDE-A694-C13EA7C0FD98
P2860
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Treatment of patients with adv ...... examethasone, and thalidomide.
@en
Treatment of patients with adv ...... examethasone, and thalidomide.
@nl
type
label
Treatment of patients with adv ...... examethasone, and thalidomide.
@en
Treatment of patients with adv ...... examethasone, and thalidomide.
@nl
prefLabel
Treatment of patients with adv ...... examethasone, and thalidomide.
@en
Treatment of patients with adv ...... examethasone, and thalidomide.
@nl
P2093
P50
P1433
P1476
Treatment of patients with adv ...... examethasone, and thalidomide.
@en
P2093
Francesca Lavatelli
Paola Russo
Remigio Moratti
Riccardo Albertini
Tiziana Bosoni
Vittorio Perfetti
P304
P356
10.1007/S00277-008-0600-Y
P577
2008-09-09T00:00:00Z